Ocrelizumab May Meaningfully Delay Loss of Ambulation, Independence in PPMS
March 22nd 2021Extrapolated comparisons from the ORATORIO trial suggest that patients with primary progressive multiple sclerosis can experience major delays in confirmed time to wheelchair requirement and disease progression.
Challenges of Targeting Cytokines in MS: Stephanie Blandford, MSc
March 21st 2021The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed the potential of interleukin-1 receptor antagonist as a biomarker in MS disability as well as a therapeutic target.